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effectiveness analysis is conducted from a societal perspective
(direct and indirect costs) and from a health care perspective
(direct costs only). Direct costs include pharmaceuticals and phy-
sician visits. Indirect costs are calculated based on production
losses (the human capital approach). The analysis uses a cost-
effectiveness model which includes effect data from two clinical
studies of gabapentin and one clinical study of pregabalin previ-
ously used in a Canadian cost-effectiveness analysis. In addition,
the analysis and treatment doses are partly based on two clinical
studies of pregabalin and gabapentin. Resource use is based on
time spent in each pain state (mild, moderate, and severe). In the
sensitivity analysis drug doses, costs, and quality of life weights
were varied. Information regarding costs, resource use, and
quality of life weights was collected from the Canadian study,
Statistics Sweden, regional price lists, Pharmaceutical Specialties
in Sweden, and from three burden of illness studies. Dr. Jörgen
Boivie was consulted regarding Swedish treatment practice.
RESULTS: Since patients treated with pregabalin spend less time
in the more severe pain states their health in terms of QALY’s is
better compared to patients treated with gabapentin (0.5019 vs.
0.4596). In the societal perspective analysis, total costs of one
year treatment were lower for pregabalin than for gabapentin
(SEK100, 476 vs. SEK102, 103). Total costs were only slightly
higher for pregabalin (SEK57,811 vs. SEK52, 645) and the cost
per QALY gained was estimated to be SEK120,000 when indirect
costs were excluded. CONCLUSION: The study shows that
pregabalin is a cost-effective and, from a societal perspective, a
cost-saving alternative compared to gabapentin in treatment of
patients with PHN.
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OBJECTIVE: To assess the cost-effectiveness of laparoscopic
adjustable gastric banding (LAGB) as treatment for morbid
obesity compared with laparoscopic roux-en-y gastric bypass
(LRGBY) and no treatment. METHODS: A Markov model was
developed to simulate weight loss, health consequences, and
costs for surgical treatment of morbid obesity. The model was
used to estimate lifetime medical-care costs, quality-adjusted life
years (QALYs) and incremental cost-effectiveness ratios (ICERs)
in terms of cost per QALY gained. Estimates of effectiveness were
derived from published results of a head-to-head randomized
controlled trial comparing LAGB and LRGBY. Patients receiving
no treatment were assumed to maintain their original weight.
Other model parameters, including complication rates, costs of
treatment and adverse events, direct medical costs attributable to
obesity, mortality rates, and utilities, were estimated from pub-
lished literature and publicly available databases. Base-case
analyses were stratiﬁed by gender and initial body mass index
(BMI). We discounted costs (2006 US dollars) and QALYs by 3%
per annum. RESULTS: Under conservative assumptions, for a
woman aged 40 years with initial BMI of 35–40, LAGB has
lower average costs than LRGBY for the initial procedure
($15,470 versus $23,160) and complications ($3680 versus
$11,930), but results in less weight loss. ICERs are $13,990
and $14,690 for LAGB and LRGBY versus no treatment; and
$16,540 for LRGBY versus LAGB. Corresponding ICERs for
women with BMIs of 40–50 are $4860, $5150, and $5780.
ICERs for men are generally higher than those of women due to
shorter life expectancies. Sensitivity analyses show results to be
robust to reasonable variation in model parameters and over-
all parameter uncertainty. CONCLUSION: Both LAGB and
LRGBY provide signiﬁcant weight loss and are cost-effective
versus no treatment at conventionally-accepted thresholds for
medical interventions. Accordingly, choice between the two pro-
cedures can be based on other factors such as patient or provider
preference.
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OBJECTIVE: To analyze the economic consequences on staff
time in post-operative wards in Sweden and Denmark of two
modalities for treatment of post-operative pain, the fentanyl
HCL iontophoretic transdermal system (fentanyl ITS) versus
patient controlled intravenous analgesia (IV-PCA). METHODS:
Current postoperative pain management is labor intensive. Fen-
tanyl ITS is a new modality for moderate-to-severe postoperative
pain. Clinical efﬁcacy and side effects incidence have been
reported as mainly the same for fentanyl ITS and IV-PCA in
several randomized clinical trials. A cost analysis was therefore
performed. Staff resources in post-operative wards were calcu-
lated based on ﬁndings from a Nordic Delphi panel where the
participants (nurses and anesthesiologists) from Sweden and
Denmark working with post-operative patients should determine
the total time required to complete all tasks involved in fentanyl
ITS and IV-PCA use and assess differences in staff time between
the alternatives. The panelists identiﬁed the following tasks: set
up, routine patient care, dosing, routine replacement, trouble-
shooting, and discontinuation of post-operative pain manage-
ment. Staff costs were calculated based on ofﬁcial wages statistics
for specialists and nurses in postoperative care. Costs were cal-
culated in 2007 prices. RESULTS: Based on the panel informa-
tion, the total post-operative staff time requirements per patient
was 70 minutes for fentanyl ITS versus 146 minutes for IV-PCA.
Most staff resources were spent on set up and routine patient care
for both treatment alternatives. The post-operative staff cost per
patient was calculated at €27 and €57 in Sweden and €31 and
€66 in Denmark, respectively. CONCLUSION: The staff costs of
post-operative management in post-operative wards with fenta-
nyl ITS is 53% (€30) lower per patient in Sweden and 53% (€35)
lower in Denmark compared with IV-PCA. Additional health-
economic analyses of total resources used for post-operative pain
management, including material costs, based on clinical obser-
vations would be valuable.
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OBJECTIVE: Corticosteroids, IVIG and Anti-D can be used as
ﬁrst-line therapy for the treatment of ITP. After review of the
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literature, Anti-D was selected over IVIG as the preferred agent
at Staten Island University Hospital. The objectives of this study
were to investigate how much IVIG was spared after implemen-
tation of this decision and determine the cost savings realized
when Anti-D is used in place of IVIG. METHODS: Literature
supporting the utilization of Anti-D in treatment of ITP was
presented by each of the key clinical faculty. The oncology phar-
macist screened and veriﬁed all IVIG orders for ITP patients.
Substitution with Anti-D was made for all Rh+ and non-
splenectomized patients. The quantity of IVIG spared was calcu-
lated by subtracting the amount dispensed before and after
implementation of the program. Savings realized were calculated
by determining the cost of a treatment course with IVIG and with
Anti-D for a 80 kg patient. RESULTS: A total of 904 and 130 g
of IVIG were administered during the ﬁrst and the second half
of 2006, respectively. Similarly, 220,000 and 376,000 units of
Anti-D were used during the same time periods. A treatment
course with IVIG (at 1 g/kg/day for two days) costs $8960
whereas a treatment course of Anti-D costs $4200 (at 75 ìg/kg).
Since the treatment of a 80 kg patient would require 160 g of
IVIG, the 774 g spared represent the amount necessary to treat
5 patients with IVIG. The sparing of 774 g of IVIG therefore
helped save $23,800. Also, 3 other courses were done with
Anti-D instead of IVIG yielding $14,280 in additional savings.
CONCLUSION: In 2006, the implementation of a therapeutic
substitution program at Staten Island University Hospital
making Anti-D the preferred agent over IVIG in the treatment of
ITP helped spare 774 grams of IVIG and saved $38,080.
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OBJECTIVE: Heparin-induced thrombocytopenia (HIT) is an
important adverse reaction associated with heparin utilization.
No previous studies have assessed the cost of suspected HIT or
examined HIT from a Canadian perspective. Therefore, the
objective of our study was to quantify the direct medical costs
associated with suspected and conﬁrmed HIT from a Canadian
hospital perspective. METHODS: A cost of illness analysis was
conducted on a population of consecutive patients with sus-
pected HIT during 2005. Suspected HIT was deﬁned by the
performance of a HIT enzyme-linked immunosorbent assay
(ELISA). Conﬁrmed HIT was deﬁned by one the following: 1)
positive serotonin release assay (SRA), 2) positive HIT ELISA
plus high clinical probability for HIT, or 3) strongly positive
HIT ELISA (optical density  1.0). Negative HIT was deﬁned
as a negative HIT ELISA or SRA result. Resource utilization
variables included: 1) HIT-safe anticoagulant use, 2) laboratory
tests, 3) diagnostic and surgical procedures, and 4) length of
stay (LOS) attributed to HIT. The average cost (2007 CAN$)
per case of conﬁrmed HIT, conﬁrmed HIT with thrombosis
(HITT), and negative HIT was calculated. Cost data was
obtained from hospital and provincial sources. RESULTS:
There were 110 suspected HIT cases (56 males: 54 females) in
2005. Two patients were excluded because their HIT status
could not be determined. Average LOS was 36  42 (range
3–244) days. There were 88 negative HIT cases, 8 with con-
ﬁrmed HIT, and 12 with conﬁrmed HITT. Patients with con-
ﬁrmed HITT incurred substantially greater average costs
($25,696, range $357–$145,217) than those with conﬁrmed
HIT ($3846, range $38–$14,258). The average cost of a nega-
tive HIT case was $115 (range $38–$4119). CONCLUSION:
This is the ﬁrst study to identify the costs associated with con-
ﬁrmed HIT, conﬁrmed HITT, and negative HIT. Suspected HIT
increases the costs of hospital care.
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OBJECTIVE: To examine literature published during the past ten
years describing the impact of obesity and obesity-related disease
on direct and indirect costs in Australia, Canada, France,
Germany, Italy, Spain, Sweden, the UK, and the US. METHODS:
A review of the medical literature published from 1997 to 2007
was conducted, including MEDLINE, EMBASE, Current
Contents Connect, and International Pharmaceutical Abstracts
databases; ISPOR abstracts; and data published by relevant gov-
ernmental agencies. RESULTS: A substantial portion of direct
costs related to obesity derive from treating comorbidities asso-
ciated with the condition (e.g., type 2 diabetes, cardiovascular
disease). Indirect costs, including those associated with reduced
work productivity, increased absenteeism, and premature death,
are signiﬁcant, with the majority arising from comorbid condi-
tions. Direct costs were greater for obese patients than for
normal-weight patients; morbid obesity was associated with dra-
matic cost increases. Estimates of direct costs as a percentage of
national health care expenditures were 5.7% for the US, and
ranged from 2% to 2.6% for Australia, Canada, Sweden, and the
UK. No estimates of indirect costs as a percentage of national
health care costs were identiﬁed. No studies involving direct or
indirect cost data collected since 1995 were identiﬁed for France,
Italy, or Spain. CONCLUSION: Obesity has a substantial eco-
nomic impact because of its high prevalence, association with
multiple chronic diseases, and increased levels of disability and
absenteeism. The lack of recent direct or indirect cost estimates in
several countries highlights the need for further work to describe
the global economic burden of obesity.
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OBJECTIVE: Conduct a systematic review of low back pain cost
of illness studies. METHODS: Medline was searched to uncover
studies about the direct or indirect costs of low back pain pub-
lished in English from 1997 to 2007. Data extracted for each
eligible study included study design, population, deﬁnition of low
back pain, methodology for estimating costs, year of data, and
estimates of direct, indirect, or total costs. RESULTS: The search
yielded 147 studies; 27 were deemed relevant. The studies
reported on data from Australia, Belgium, Japan, Korea, The
Netherlands, Sweden, the UK, and the US. Nine studies estimated
direct costs only, 9 indirect costs only, and 9 both direct and
indirect costs, from a societal (n = 18) or private insurer (n = 9)
perspective. Methodology used to derive both direct and indirect
cost estimates differed markedly among the studies. Among
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